InVivoMAb anti-mouse PSGL-1 (CD162)

Guidotti LG, Inverso D, Sironi L, et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell. 2015,161(3):486-500. doi: 10.1016/j.cell.2015.03.005

Biswas A, Bruder D, Wolf SA, et al. Ly6C(high) monocytes control cerebral toxoplasmosis. J Immunol. 2015,194(7):3223-35. doi: 10.4049/jimmunol.1402037

McPherson RC, Konkel JE, Prendergast CT, et al. Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy. Elife. 2014,3. doi: 10.7554/eLife.03416

Yokota N, Zarpellon A, Chakrabarty S, et al. Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost. 2014,12(1):71-81. doi: 10.1111/jth.12442

Rivera-Nieves J, Burcin TL, Olson TS, et al. Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med. 2006,203(4):907-17.

Zanardo RC, Bonder CS, Hwang JM, et al. A down-regulatable E-selectin ligand is functionally important for PSGL-1-independent leukocyte-endothelial cell interactions. Blood. 2004,104(12):3766-73.